文献速递产科麻醉疼痛医学

0.35%左布比卡因伤口输注减少剖宫产术后机械性次级痛觉过敏和阿片类药物消耗:一项前瞻性、随机、三盲、安慰剂对照试验

Wound Infusion of 0.35% Levobupivacaine Reduces Mechanical Secondary Hyperalgesia and Opioid Consumption After Cesarean Delivery: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Trial.
PubMed 文献 · Anesth Analg · 2022-01-01

结果显示左布比卡因组24和48小时次级痛觉过敏面积显著减小,24小时机械痛阈显著升高,24小时吗啡消耗量显著降低,但未影响术后1、3、6、12个月的持续性疼痛。

要点

  • 左布比卡因伤口输注显著缩小剖宫产术后24和48小时机械性次级痛觉过敏面积。
  • 左布比卡因组24小时机械痛阈升高且24小时吗啡消耗量显著降低。
  • 左布比卡因对术后1、3、6、12个月持续性疼痛无显著影响。

核心结论

  • 0.35%左布比卡因伤口输注提供充分镇痛,并可能作为有效的抗痛觉过敏辅助手段。

研究设计与样本

  • 所有患者接受0.5%高比重布比卡因复合芬太尼腰麻,并置入筋膜下多孔伤口导管。
  • 随机分为左布比卡因组(0.35%左布比卡因7 mL/h持续48小时)和生理盐水组(等体积生理盐水)。

主要发现

  • 左布比卡因对术后1、3、6、12个月持续性疼痛无显著影响。

临床怎么用

  • 剖宫产术后可考虑筋膜下持续伤口输注0.35%左布比卡因7 mL/h持续48小时,以减轻机械性次级痛觉过敏并减少早期阿片类药物消耗。
  • 该方案对长期持续性疼痛的预防作用未获证实,临床决策需结合患者个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some patients still report moderate-to-severe postoperative pain after cesarean delivery. Local anesthetic wound infusion improves acute pain and might act on peripheral and central sensitization mechanisms; however, no studies have proved this hypothesis. We evaluated the potential benefits of continuous wound infusion of levobupivacaine after cesarean delivery on secondary hyperalgesia (primary end point) and primary hyperalgesia, pain relief, persistent pain, and inflammatory and metabolic stress response. METHODS: Healthy women scheduled for elective cesarean delivery participated in this prospective, randomized, triple-blind, placebo-controlled trial (NCT01458431). All patients received spinal anesthesia with 0.5% hyperbaric bupivacaine with fentanyl and a multiholed wound catheter placed under the fascia. Women were randomized to receive continuous wound infusion (0.35% levobupivacaine 7 mL/h for 48 hours; group L) or an equal volume of saline (group S). Secondary hyperalgesia to punctate mechanical stimuli was evaluated using dynamic tests, and primary hyperalgesia was evaluated using an electronic von Frey anesthesiometer; both were assessed at 24, 48, and 72 hours. The following variables were collected: intensity of postoperative parietal and visceral pain at rest and on movement rated on a visual analog scale >72 hours, time to first bolus of patient-controlled analgesia (PCA), cumulative dose of rescue morphine (PCA) and acetaminophen, ability to sleep and sleep quality, and patient satisfaction. Persistent postoperative pain was evaluated during a telephone interview at 1, 3, 6, and 12 months after surgery. C-reactive protein, acid glycoprotein, preprandial glucose, insulin, cortisol, prolactin, growth hormone, and interleukin-6 were measured before cesarean delivery and at 8, 24, and 48 hours. Adverse events and patient outcomes were recorded. RESULTS: Seventy women were included. In group L, the area of secondary hyperalgesia was significantly reduced (43.4 [18.5-80] vs 68.4 [39.0-136] cm2 and 45.1 [0.9-89.8] vs 67.3 [31.3-175] cm2 at 24 and 48 hours, respectively; group:time interaction P value < .001), the mechanical pain threshold was significantly higher at 24 hours (633 [441-802] vs 417 [300-572] g.mm-2; P = .001), and morphine consumption was significantly lower at 24 hours (4 [2-11] vs 11[6-23]; P = .003) compared with group S. Levobupivacaine had no effect on persistent postoperative pain at 1, 3, 6, and 12 months. Plasma insulin levels in the immediate postoperative period and at 8, 24, and 48 hours were significantly lower in group L (P < .001). There were no significant differences in other biochemical parameters of inflammatory and endocrine-metabolic response. CONCLUSIONS: Levobupivacaine wound infusion provides adequate analgesia and might be an effective antihyperalgesic adjunct.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Gómez-Ríos MÁ, Codesido-Barreiro P, Seco-Vilariño C, et al. Wound Infusion of 0.35% Levobupivacaine Reduces Mechanical Secondary Hyperalgesia and Opioid Consumption After Cesarean Delivery: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Trial. Anesth Analg. 2022. PMID: 35086112. doi:10.1213/ANE.0000000000005917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。